Trials / Completed
CompletedNCT00144976
Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma
Pilot Study, Without Direct Individual Benefice, of Biological Effect of Tarceva (OSI-774) at Posology of 150 mg by Day for Patients Stricken by ENT Epidermoid Carcinoma Waiting for First Surgical Picking up.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Institut Claudius Regaud · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the biological effect of Tarceva (OSI-774) from an inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.
Detailed description
Patients will receive Tarceva in continuous between 18 and 28 days after pan-endoscopy exam until surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarceva | Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days. |
Timeline
- Start date
- 2003-10-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2005-09-05
- Last updated
- 2015-03-27
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00144976. Inclusion in this directory is not an endorsement.